According to the company, the global 3D bioprinting market is growing at a CAGR of 14.52% from 2013 to 2018. The new technique is already transforming drug screening and fundamental studies of wound healing, angiogenesis and stem-cell niches. It is helping reduce the risk of drug failure during pre-clinical trial testing, thus minimising the complications related to human trials.
Key players in the market named by TechNavio include 3D Systems, Envision TEC, Organovo Holdings and Stratasys.
“Many cosmetic and pharmaceutical companies are collaborating with 3D bioprinting companies to ease the drug discovery process and avoid testing on animals. For instance, Roche collaborated with Organovo to produce liver tissue, which is helping Roche produce a toxin-free drug. Innovations like this will be a huge factor affecting market growth over the next four years,” says Faisal Ghaus, Vice President of TechNavio.
“Many cosmetic and pharmaceutical companies are collaborating with 3D bioprinting companies to ease the drug discovery process and avoid testing on animals. For instance, Roche collaborated with Organovo to produce liver tissue, which is helping Roche produce a toxin-free drug. Innovations like this will be a huge factor affecting market growth over the next four years,” says Faisal Ghaus, Vice President of TechNavio.
No comments:
Post a Comment